RxDoctor Payments Data

Stephen Gollomp, MD

Neurology · Wynnewood, PANPI 1194723585

Payments from drug & device makers

$144,488in general payments, 2019–2025

Across 778 payments — averaging $185.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$54K
  • Merz North America, Inc.$29K
  • AbbVie$14K
  • Merz Pharmaceuticals, LLC$14K
  • Sunovion Pharmaceuticals Inc.$9K
  • Kyowa Kirin, Inc.$7K
  • plus $18K from 52 others

What the payments were for

  • Consulting fees$35,40425%
  • Speaking & faculty fees$74,59752%
  • Travel & lodging$15,89711%
  • Food & beverage$16,85912%
  • Education$1,7311%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neurocrine Biosciences, Inc.73$54,467
Merz North America, Inc.30$29,214
AbbVie(2 entities)126$13,986
Merz Pharmaceuticals, LLC37$13,664
Sunovion Pharmaceuticals Inc.25$8,598
Kyowa Kirin, Inc.15$7,009
Boston Scientific23$2,486
MDD US Operations, LLC13$2,265
Acadia Pharmaceuticals Inc30$2,217
Amneal Pharmaceuticals LLC36$1,839
Lilly USA, LLC42$817
Biogen32$740
Abbott9$679
SK Life Science, Inc.29$679
Teva Pharmaceuticals USA, Inc.30$594
Novartis16$389
Pfizer21$361
Medtronic(2 entities)7$342
Argenx US, Inc.13$327
UCB, Inc.20$315
AstraZeneca14$288
TG Therapeutics, Inc.8$258
Amgen10$251
Genentech USA, Inc.10$222
Insightec,inc2$199
Sumitomo Pharma America, Inc.8$182
Johnson & Johnson6$164
Acorda Therapeutics, Inc7$141
Sanofi6$127
Eisai Inc.6$122
Idorsia Pharmaceuticals US Inc1$116
Biohaven Pharmaceuticals, Inc.6$115
GE HealthCare6$112
Avanir Pharmaceuticals, Inc.6$108
Greenwich Biosciences, Inc.2$107
Biohaven Pharmaceutical Holding Company Ltd.5$101
EMD Serono, Inc.5$99
Lundbeck LLC5$94
Adamas Pharmaceuticals, Inc.5$91
Bristol Myers Squibb4$82
Upsher-smith Laboratories LLC4$79
Xeris Pharmaceuticals, Inc.3$58
Sanofi-aventis U.S. LLC2$50
Avion Pharmaceuticals2$39
Vertical Pharmaceuticals, LLC2$37
Jazz Pharmaceuticals Inc.2$35
Impel Pharmaceuticals LLC2$32
Akcea Therapeutics, Inc.2$22
Portola Pharmaceuticals, LLC1$20
Banner Life Sciences, LLC1$19
Ipsen Biopharmaceuticals, Inc1$19
Impel Pharmaceuticals Inc.1$18
Livanova USA, Inc.1$17
Neurelis, Inc.1$15
Otsuka America Pharmaceutical, Inc.1$15
Novo Nordisk1$14
Amarin Pharma, Inc.1$14
Revance Therapeutics, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$144,488 in reported general payments places this provider in the 85th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$590,723
Medicare patients
529
Services billed
49,485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate45$456,224
AustedoDeutetrabenazine19$258,064
TecfideraDimethyl Fumarate24$225,667
NuplazidPimavanserin Tartrate23$151,223
GocovriAmantadine Hcl26$95,557
RytaryCarbidopa/Levodopa41$54,858
OngentysOpicapone25$26,829
Aimovig AutoinjectorErenumab-Aooe25$20,718
Carbidopa-LevodopaCarbidopa/Levodopa554$18,317
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone49$16,738
Selegiline Hcl128$13,958
Carbidopa-Levodopa ErCarbidopa/Levodopa176$10,223
KeppraLevetiracetam13$7,044
Rasagiline Mesylate42$5,320
Propranolol Hcl ErPropranolol Hcl90$4,553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$54,467$483,05370 claims
Teva Pharmaceuticals USA, Inc.Austedo$594$258,06419 claims
BiogenTecfidera$740$225,66724 claims
Acadia Pharmaceuticals IncNuplazid$2,217$151,22323 claims
MDD US Operations, LLCGocovri$2,265$95,55726 claims
Amneal Pharmaceuticals LLCRytary$1,839$54,85841 claims
Upsher-smith Laboratories LLCTopiramate$79$63926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →